Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis From the SUNSHINE and SUNRISE Phase 3 Trials

Main Article Content

Alexa B Kimball
Afsaneh Alavi
Gregor BE Jemec
Alice Gottlieb
Xiaoling Wei
Magdalena B Wozniak
Lorenz Uhlmann
Angela Llobet Martinez
Deborah Keefe
Ruvie Martin
Li Chen
Elisa Muscianisi


Hidradenitis suppurativa, acne inversa, secukinumab, IL-17, Phase 3, HiSCR


1. Frew J. JAAD Int. 2020;1(1):62-72.

2. Ingram JR, et al. Eur Acad Dermatol Venereol. 2022;36(9):1597-1605.

3. Zouboulis CC, et al. Exp Dermatol. 2021;30(Suppl 1):8-17.

Most read articles by the same author(s)

1 2 > >>